Loading...

Tianhong Li, MD; PhD

Title(s)Associate Professor, Hematology and Oncology
SchoolUniversity of California, Davis
AddressCancer Ctr So, #3016
CA 95817
Phone916-734-3772
ORCID ORCID Icon0000-0001-7422-3520 Additional info
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Managing the Isolated Central Nervous System Progression in Patients With Oncogene-Driven Metastatic NSCLC: Does Circulating Tumor DNA Add to Management? J Thorac Oncol. 2020 Mar; 15(3):314-316. Li T. PMID: 32093852.
      View in: PubMed   Mentions:    Fields:    
    2. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors. Cancer Treat Res. 2020; 180:251-279. Chen JA, Ma W, Yuan J, Li T. PMID: 32215873.
      View in: PubMed   Mentions:    Fields:    
    3. Speeding Access to Precision Oncology Drugs: How Are We Doing With Biomarker-Driven Drug Approvals? J Natl Compr Canc Netw. 2020 01; 18(1):113-114. Li T. PMID: 31910383.
      View in: PubMed   Mentions:    Fields:    
    4. Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non-small-cell Lung Cancer. Clin Lung Cancer. 2020 Jan; 21(1):e15-e20. Al-Obeidi E, Li T, Kelly K. PMID: 31649001.
      View in: PubMed   Mentions:    Fields:    
    5. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 Jan 15; 26(2):439-449. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. PMID: 31548343.
      View in: PubMed   Mentions:    Fields:    
    6. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. Transl Lung Cancer Res. 2019 Aug; 8(4):429-449. Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y, Zhang Q, Zhang F, Liu H, Li T, Sugimura H, Cappuzzo F, Lin D, Lv T. PMID: 31555517.
      View in: PubMed   Mentions:
    7. Correction to: High-affinity peptide ligand LXY30 for targeting a3ß1 integrin in non-small cell lung cancer. J Hematol Oncol. 2019 Jul 26; 12(1):83. Xiao W, Ma W, Wei S, Li Q, Liu R, Carney RP, Yang K, Lee J, Nyugen A, Yoneda KY, Lam KS, Li T. PMID: 31349855.
      View in: PubMed   Mentions:    Fields:    
    8. High-affinity peptide ligand LXY30 for targeting a3ß1 integrin in non-small cell lung cancer. J Hematol Oncol. 2019 06 10; 12(1):56. Xiao W, Ma W, Wei S, Li Q, Liu R, Carney RP, Yang K, Lee J, Nyugen A, Yoneda KY, Lam KS, Li T. PMID: 31182116.
      View in: PubMed   Mentions: 1     Fields:    
    9. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res. 2019 Jun; 8(3):286-301. Gregg JP, Li T, Yoneda KY. PMID: 31367542.
      View in: PubMed   Mentions:
    10. Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors. J Natl Compr Canc Netw. 2019 04 01; 17(4):297-301. Gong J, Gregg JP, Ma W, Yoneda K, Moore EH, Daly ME, Zhang Y, Williams MJ, Li T. PMID: 30959466.
      View in: PubMed   Mentions: 1     Fields:    
    11. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303). Front Oncol. 2019; 9:132. Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN. PMID: 30915273.
      View in: PubMed   Mentions:
    12. Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC. Chin Clin Oncol. 2019 Oct; 8(S1):S4. Li T, Ma W, Tian EC. PMID: 30525756.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors. J Hematol Oncol. 2018 11 06; 11(1):129. Zhou C, Yuan Z, Ma W, Qi L, Mahavongtrakul A, Li Y, Li H, Gong J, Fan RR, Li J, Molmen M, Clark TA, Pavlick D, Frampton GM, Forcier B, Moore EH, Shelton DK, Cooke M, Ali SM, Miller VA, Gregg JP, Stephens PJ, Li T. PMID: 30400986.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Safety and Efficacy of Osimertinib in the Treatment of a Patient With Metastatic Lung Cancer and Concurrent Somatic EGFR L858R and Germline EGFR T790M Mutations. JCO Precision Oncology. 2018 Nov 1; (2):1-7. Weijie Ma, Jay Gong, Jidong Shan, Debbie Lewis, Wenwu Xiao, Elizabeth H. Moore, Yanhong Zhang, Jamie Hung, Nicole Z. Mans, Sixi Wei, Jenna Welborn, Nicholas S. Stollenwerk, Kit S. Lam, Tianhong Li. .
      View in: Publisher Site   Mentions:
    15. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 02; 14(2):255-264. Schrock AB, Welsh A, Chung JH, Pavlick D, Bernicker EH, Creelan BC, Forcier B, Ross JS, Stephens PJ, Ali SM, Dagogo-Jack I, Shaw AT, Li T, Ou SI, Miller VA. PMID: 30368012.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer. J Thorac Dis. 2018 Sep; 10(Suppl 26):S3186-S3191. Li Q, Ma W, Li T. PMID: 30430029.
      View in: PubMed   Mentions:
    17. The Tsinghua-Lancet Commission on Healthy Cities in China: unlocking the power of cities for a healthy China. Lancet. 2018 05 26; 391(10135):2140-2184. Yang J, Siri JG, Remais JV, Cheng Q, Zhang H, Chan KKY, Sun Z, Zhao Y, Cong N, Li X, Zhang W, Bai Y, Bi J, Cai W, Chan EYY, Chen W, Fan W, Fu H, He J, Huang H, Ji JS, Jia P, Jiang X, Kwan MP, Li T, Li X, Liang S, Liang X, Liang L, Liu Q, Lu Y, Luo Y, Ma X, Schwartländer B, Shen Z, Shi P, Su J, Wu T, Yang C, Yin Y, Zhang Q, Zhang Y, Zhang Y, Xu B, Gong P. PMID: 29678340.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    18. Src activation decouples cell division orientation from cell geometry in mammalian cells. Biomaterials. 2018 07; 170:82-94. Sun X, Qi H, Zhang X, Li L, Zhang J, Zeng Q, Laszlo GS, Wei B, Li T, Jiang J, Mogilner A, Fu X, Zhao M. PMID: 29653289.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    19. Durable Local Control Following Concurrent Hypofractionated Chemoradiation for a Massive Inflammatory Breast Cancer Chest Wall Recurrence. Cureus. 2017 Jun 21; 9(6):e1379. Dyer BA, Nguyen KNB, Shukla RP, Li T, Daly ME. PMID: 28775919.
      View in: PubMed   Mentions:
    20. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. J Hematol Oncol. 2017 02 28; 10(1):64. Li H, Ma W, Yoneda KY, Moore EH, Zhang Y, Pu LL, Frampton GM, Molmen M, Stephens PJ, Li T. PMID: 28245875.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    21. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN. PMID: 28082049.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):60-67. Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN, Gandara DR, Perez-Soler R. PMID: 27919627.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    23. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016 Oct 21; 27(42):425103. Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. PMID: 27640312.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    24. Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer. Biomaterials. 2016 10; 104:339-51. Lin TY, Li Y, Liu Q, Chen JL, Zhang H, Lac D, Zhang H, Ferrara KW, Wachsmann-Hogiu S, Li T, Airhart S, deVere White R, Lam KS, Pan CX. PMID: 27479049.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    25. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016 05 27; 9(1):47. Ma W, Gilligan BM, Yuan J, Li T. PMID: 27234522.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    26. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. J Hematol Oncol. 2016 Mar 10; 9:23. Li T, LoRusso P, Maitland ML, Ou SH, Bahceci E, Ball HA, Park JW, Yuen G, Tolcher A. PMID: 26966027.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    27. Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of a3 integrin-expressing human tumors. EJNMMI Res. 2016 Dec; 6(1):18. Xiao W, Li T, Bononi FC, Lac D, Kekessie IA, Liu Y, Sanchez E, Mazloom A, Ma AH, Lin J, Tran J, Yang K, Lam KS, Liu R. PMID: 26922417.
      View in: PubMed   Mentions:
    28. Re: Ling Y-H, Li T, Yuan Z, Haigentz M, Jr., Weber TK, and Perez-Soler R (2007) Erlotinib, an Effective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces p27KIP1 Up-Regulation and Nuclear Translocation in Association with Cell Growth Inhibition and G1/S Phase Arrest in Human Non-Small-Cell Lung Cancer Cell Lines. Mol Pharmacol 72:248-258; doi:10.1124/mol.107.034827. Mol Pharmacol. 2015 Aug; 88(2):390. PMID: 26130289.
      View in: PubMed   Mentions:    Fields:    
    29. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. PMID: 26106072.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    30. Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization. J Pharmacol Exp Ther. 2015 Aug; 354(2):131-41. Wang WP, Ho PY, Chen QX, Addepalli B, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, White RD, Lam KS, Yu AM. PMID: 26022002.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    31. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. PMID: 25838158.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    32. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2480-6. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN. PMID: 25739672.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    33. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol. 2014 Jan; 9(1):18-25. Li T, Maus MK, Desai SJ, Beckett LA, Stephens C, Huang E, Hsiang J, Zeger G, Danenberg KD, Astrow SH, Gandara DR. PMID: 24346090.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    34. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. PMID: 24176733.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    35. Retraction: The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clin Cancer Res. 2013 Sep 01; 19(17):4901. Perez-Soler R, Zou Y, Li T, Ling YH. PMID: 24003062.
      View in: PubMed   Mentions: 1     Fields:    
    36. CTEN prolongs signaling by EGFR through reducing its ligand-induced degradation. Cancer Res. 2013 Aug 15; 73(16):5266-76. Hong SY, Shih YP, Li T, Carraway KL, Lo SH. PMID: 23774213.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    37. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol. 2013 May; 8(5):582-6. Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara DR. PMID: 23470290.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    38. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013 Mar 10; 31(8):1039-49. Li T, Kung HJ, Mack PC, Gandara DR. PMID: 23401433.
      View in: PubMed   Mentions: 120     Fields:    Translation:Humans
    39. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012 Sep; 13(5):321-5. Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. PMID: 22677432.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    40. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). Breast Cancer Res Treat. 2012 Jul; 134(1):345-52. Li T, Guo M, Gradishar WJ, Sparano JA, Perez EA, Wang M, Sledge GW. PMID: 22547107.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    41. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9. Sangha R, Davies AM, Lara PN, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. PMID: 21892109.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    42. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clin Cancer Res. 2011 Nov 01; 17(21):6766-77. Perez-Soler R, Zou Y, Li T, Ling YH. PMID: 21914790.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    43. Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes? J Thorac Dis. 2010 Dec; 2(4):189-91. Li T. PMID: 22263043.
      View in: PubMed   Mentions:
    44. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):1933-8. Gandara DR, Grimminger P, Mack PC, Lara PN, Li T, Danenberg PV, Danenberg KD. PMID: 20975603.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    45. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr; 30(2):741-8. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN, Gandara DR. PMID: 20967484.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    46. [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi. 2010 Mar; 13(3):238-41. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. PMID: 20681067.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. Curr Drug Targets. 2010 Jan; 11(1):85-94. Li T, Lara PN, Mack PC, Perez-Soler R, Gandara DR. PMID: 19839922.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    48. Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts. PLoS One. 2009 Nov 16; 4(11):e7774. Pohl NM, Tong C, Fang W, Bi X, Li T, Yang W. PMID: 19924303.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    49. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer. 2009 Nov; 10(6):392-4. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. PMID: 19900855.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    50. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer. 2010 Apr; 68(1):89-93. Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp R. PMID: 19524318.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    51. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009 Apr; 4(2):107-19. Li T, Perez-Soler R. PMID: 19452131.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimals
    52. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res. 2009 Apr 15; 15(8):2942-8. Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM. PMID: 19351752.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    53. Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Ann Oncol. 2009 Apr; 20(4):642-7. Li T, Christos PJ, Sparano JA, Hershman DL, Hoschander S, O'Brien K, Wright JJ, Vahdat LT. PMID: 19153124.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    54. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Cancer Chemother Pharmacol. 2009 Aug; 64(3):539-48. Ling YH, Li T, Perez-Soler R, Haigentz M. PMID: 19130057.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    55. Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res. 2008 Nov; 52(11):1289-99. Li T, Yang W, Li M, Byun DS, Tong C, Nasser S, Zhuang M, Arango D, Mariadason JM, Augenlicht LH. PMID: 18435490.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    56. Farnesyl transferase inhibitors. Cancer Invest. 2008 Aug; 26(7):653-61. Li T, Sparano JA. PMID: 18665473.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    57. Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene. J Thorac Oncol. 2008 Jun; 3(6):643-7. Li T, Ling YH, Perez-Soler R. PMID: 18520805.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    58. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 2007 Jun 01; 13(11):3413-22. Li T, Ling YH, Goldman ID, Perez-Soler R. PMID: 17545550.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    59. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol. 2007 Aug; 72(2):248-58. Ling YH, Li T, Yuan Z, Haigentz M, Weber TK, Perez-Soler R. PMID: 17456787.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    60. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol. 2006 Jul 01; 24(19):3013-8. Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM. PMID: 16769985.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    61. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol. 2006 Jun; 168(6):1998-2013. Li T, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG, Sparano JA, Lisanti MP. PMID: 16723714.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    62. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol. 2004 Apr 15; 22(8):1491-500. Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, Henry DH, Manalo J, Li T, Von Roenn JH. PMID: 15084622.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    63. Inhibiting Ras signaling in the therapy of breast cancer. Clin Breast Cancer. 2003 Feb; 3(6):405-16; discussion 417-20. Li T, Sparano JA. PMID: 12636885.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    64. Construction and expression of a soluble form of human CD30 ligand with functional activity. J Leukoc Biol. 1998 Jun; 63(6):752-7. Powell IF, Li T, Jäck HM, Ellis TM. PMID: 9620669.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    Tianhong's Networks
    Concepts (293)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (46)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑